Farxiga approved in the US for the treatment of paediatric type-2 diabetes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
There was no observation related to data integrity reported
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
EDQM has also issued a Certificate of Suitability for Allopurino
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Subscribe To Our Newsletter & Stay Updated